MedTrace Logo

Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

NCT03867045 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-06-14

No results posted yet for this study

Summary

The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.

Conditions

  • Metastatic Renal Cell Carcinoma Treated With Cabozantinib

Interventions

DEVICE

Usability of an electronic symptom management application

Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users

Sponsors & Collaborators

Principal Investigators

  • Sundhar Ramalingam, MD · Duke University

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2019-12-16
Completion
2019-12-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867045 on ClinicalTrials.gov